FindTrial
Sign In

The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis: a prospective single blind unicenter randomized clinical trial - The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis

The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis: a prospective single blind unicenter randomized clinical trial - The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-010863-18-NL
Enrollment
90
Registered
2009-03-13
Start date
2010-06-25
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis patient getting UVB lighttherapy in a dermatological daycare center MedDRA version: 9.1 Level: LLT Classification code 10015581 Term: Exacerbation of psoriasis MedDRA version: 9.1 Level: LLT Classification code 10037153 Term: Psoriasis MedDRA version: 9.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris

Interventions

Product Name: coal tar solution (koolteeroplossing-vaselineceme 20%) Pharmaceutical Form: Cream INN or Proposed INN: coal tar solution CAS Number: 8050439 Other descriptive name: COAL TAR SOLUTION Con

Sponsors

Amphia ziekenhuis
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Psoriasis vulgaris Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: contraindications of UVB-therapy or tar application

Design outcomes

Primary

MeasureTime frame
Main Objective: The amount of UVB sessions needed until clearance of psoriatic lesions ;Secondary Objective: The amount of joules needed untill clearance Clearance of psoriasis after the full treatment period Time until exacerbation after therapy Quality of life Monitoring of subjective complaints and side effects ;Primary end point(s): clear defined as PASI 90—

Countries

Netherlands

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026